-
Medilink Therapeutics Partners with BioNTech to Develop ADC Products Using TMALIN Technology
•
Medilink Therapeutics, based in Suzhou, has entered into another partnership agreement with German biotechnology company BioNTech SE (NASDAQ: BNTC). This collaboration allows BioNTech to utilize Medilink’s TMALIN ADC technology platform for the development of specific antibody drug conjugate (ADC) products. According to the terms of the deal, BioNTech will make…
-
BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers
•
German biotechnology company BioNTech SE (NASDAQ: BNTC) and its partner Duality Biologics (Suzhou) Co., Ltd have received fast-track designation from the U.S. Food and Drug Administration for their jointly developed drug candidate DB-1305/BNT325. This designation is in recognition of the drug’s potential to treat platinum-resistant epithelial ovarian cancer, fallopian tube…
